← All trials
NCT04421404
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 8, 2020
- Primary completion
- Apr 30, 2021
- Completion date
- Apr 30, 2021
- First posted
- Jun 9, 2020
- Last posted
- Jun 9, 2020
- Enrollment
- 30
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of California, San FranciscoLead sponsor
- University of California, San FranciscoCollaborator
- University of California, San FranciscoSponsor investigator
- University of California, San FranciscoOverall official - principal investigator
- Blood Systems Research InstituteCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.